Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
For Oncology, 2021 is a breakthrough year of delivering
transformative innovation
Readouts
177Lu-PSMA-617 Ph3 - mCRPC
Submissions
JAKAVI
ruxolitinib
Iptacopan
Ph2 - PNH
Canakinumab Ph3 NSCLC 2L
TABRECTA
(capmatinib) tablets
Asciminib
Alpelisib
Ph3 - PROS
KYMRIAH™
(tisagenlecleucel)
Ph2 - FL
KYMRIAH™
(tisagenlecleucel)
Ph3 GEP NET (OS)
LUTATHERA
Designations
EU, JP in a/c GVHD
Asciminib
FDA BTD in 3L CML
EU in NSCLC
Sabatolimab
FDA Fast Track in MDS
US, EU in CML 3L
Alpelisib
177Lu-PSMA-617
EU Orphan designation in PROS
FDA BTD in mCRPC
177Lu-PSMA-617 US, EU in mCRPC
KYMRIAH™
(tisagenlecleucel);
Spenden
for infusan
Canakinumab
US, EU and JP in FL
US in aNHL 2L
Canakinumab Ph3 NSCLC 1L
US in NSCLC 1L1
KYMRIAH™
(tisagenlecleucel) fr
Ph2aNHL 2L
S
Tislelizumab
US in 2L ESCC
KISQALI
ribociclib
Ph3 - HR+ HER2- ABC
(M-2 OS)
Tislelizumab
US in NSCLC
Alpelisib
US in PROS
1. Depending on timing of final read-out submission may move to early 2022
31 Investor Relations | Q2 2021 Results
✓ Achieved
Readout not supportive
1 NOVARTIS | Reimagining MedicineView entire presentation